2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 507

Comparison of Body Mass Index, Anti-Citrullinated Peptides Antibodies Status and Periodontal Condition in First Degree Relatives Individuals to Rheumatoid Arthritis
Abstract Number: 508

Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms
Abstract Number: 509

Association of Anti-Citrullinated Protein Antibody Positivity and Titer Levels to Low Hand BMD, and the Consequence of Low Hand BMD on DAS28 (CRP) Remission in Established RA: Findings from a US Observational Cohort
Abstract Number: 510

C-Reactive Protein and Disease Activity in Rheumatoid Arthritis: Impact of Obesity and Adiposity
Abstract Number: 511

Complement C3 and C4 Levels and Its Correlation with Disease Activity in Rheumatoid Arthritis Patients
Abstract Number: 512

Anti-Cyclic Citrullinated Protein Antibody (ACPA) Positivity in General Population and Follow-up Results for ACPA Positive Persons
Abstract Number: 513

Low Serum 25-Hydroxyvitamin D Level Is Not Associated with Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis
Abstract Number: 514

Gender Difference Is Apparent in the Risk of Forefoot Deformity in Patients with Rheumatoid Arthritis
Abstract Number: 515

The Association of Body Mass Index with the Severity of Magnetic Resonance Imaging-Detected Inflammation at Presentation; Opposite Effects in Early Rheumatoid Arthritis Compared to Other Arthritides and an Asymptomatic Population
Abstract Number: 516

Development of RA Patient Preference Phenotypes
Abstract Number: 517

Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis
Abstract Number: 518

Contribution of Patient Global Assessment on Loss and Gain of Disease Remission in Patients with Established Rheumatoid Arthritis in Clinical Practice
Abstract Number: 519

Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom
Abstract Number: 520

The HAQ Reversible and Irreversible Components Measuring Function in Rheumatoid Arthritis
Abstract Number: 521

Subcutaneous Adipose Tissue from Rheumatoid Arthritis Patients Is Characterized By an Abundance of Macrophages That Are Associated with Autoantibodies, Systemic Inflammation, and Immunomodulation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].